Bio Techne Ownership
| TECH Stock | USD 75.36 0.02 0.03% |
Shares in Circulation | First Issued 2009-03-31 | Previous Quarter 161 M | Current Value 161 M | Avarage Shares Outstanding 153.6 M | Quarterly Volatility 5.9 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Bio |
Bio Stock Ownership Analysis
About 99.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 2.77. Bio Techne Corp last dividend was issued on the 8th of November 2024. The entity had 4:1 split on the 30th of November 2022. Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota. Bio-Techne operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3000 people. To find out more about Bio Techne Corp contact Charles Kummeth at 612 379 8854 or learn more at https://www.bio-techne.com.Besides selling stocks to institutional investors, Bio Techne also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Bio Techne's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Bio Techne's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Bio Techne Quarterly Liabilities And Stockholders Equity |
|
Bio Techne Insider Trades History
Only 1.03% of Bio Techne Corp are currently held by insiders. Unlike Bio Techne's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Bio Techne's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Bio Techne's insider trades
Bio Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Bio Techne is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bio Techne Corp backward and forwards among themselves. Bio Techne's institutional investor refers to the entity that pools money to purchase Bio Techne's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Mackenzie Investments | 2024-09-30 | 2.9 M | Mairs & Power Inc | 2024-09-30 | 2.7 M | Champlain Investment Partners, Llc | 2024-09-30 | 2.6 M | Massachusetts Financial Services Company | 2024-09-30 | 2.6 M | Macquarie Group Ltd | 2024-09-30 | 2.5 M | Bank Of New York Mellon Corp | 2024-09-30 | 2.4 M | Brown Capital Management, Llc | 2024-09-30 | 2.1 M | Norges Bank | 2024-06-30 | 1.9 M | Select Equity Group Lp | 2024-09-30 | 1.8 M | Vanguard Group Inc | 2024-09-30 | 18.3 M | Blackrock Inc | 2024-06-30 | 15 M |
Bio Techne Corp Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bio Techne insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bio Techne's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bio Techne insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kim Kelderman over two months ago Acquisition by Kim Kelderman of 1492 shares of Bio Techne at 66.97 subject to Rule 16b-3 | ||
Kim Kelderman over three months ago Acquisition by Kim Kelderman of 1492 shares of Bio Techne at 66.97 subject to Rule 16b-3 | ||
Klimovsky Judith V over six months ago Insider Trading | ||
Harold Wiens over a year ago Bio Techne exotic insider transaction detected | ||
Rupert Vessey over a year ago Acquisition by Rupert Vessey of 1625 shares of Bio Techne subject to Rule 16b-3 | ||
Harold Wiens over a year ago Bio Techne exotic insider transaction detected | ||
Harold Wiens over a year ago Bio Techne exotic insider transaction detected |
Bio Techne Outstanding Bonds
Bio Techne issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bio Techne Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bio bonds can be classified according to their maturity, which is the date when Bio Techne Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Bio Techne Corporate Filings
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 8th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 5th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 30th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Currently Active Assets on Macroaxis
When determining whether Bio Techne Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Techne's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Techne Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Techne Corp Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Bio Techne Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Techne. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Techne listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.32) | Dividend Share 0.32 | Earnings Share 0.95 | Revenue Per Share 7.424 | Quarterly Revenue Growth 0.045 |
The market value of Bio Techne Corp is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Techne's value that differs from its market value or its book value, called intrinsic value, which is Bio Techne's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Techne's market value can be influenced by many factors that don't directly affect Bio Techne's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Techne's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Techne is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Techne's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.